ERAS — 13F Filings Explorer

Erasca, Inc. entered into an underwriting agreement to sell 31,428,572 shares of common stock at $17.50 per share. The company expects net proceeds of approximately $516 million, or $593.5 million if underwriters exercise their option to purchase additional shares. The offering is expected to close on July 15, 2026.

Erasca, Inc. announced updated Phase 1 data for its experimental drug ERAS-0015, a pan-RAS molecular glue. In a seven-patient subgroup with a specific type of pancreatic cancer at the recommended dose, 57% had a confirmed or unconfirmed response within eight weeks. The company also reported no dose-limiting toxicities in a combination study with panitumumab for colorectal cancer. Erasca plans to start registration-enabling trials in non-small cell lung cancer and pivotal Phase 3 trials in pancreatic cancer in 2027.

Erasca, Inc. held its annual meeting on June 26, 2026. Shareholders voted to elect three Class II directors—Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.—each receiving over 219 million votes in favor. They also ratified KPMG LLP as the independent accounting firm for fiscal 2026 with about 264.6 million votes in favor, 1.4 million withheld, and 70,000 against.